KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Goodwill & Intangibles: 2020-2024

Historic Goodwill & Intangibles for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $484.7 million.

  • Recursion Pharmaceuticals' Goodwill & Intangibles rose 462.27% to $484.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $484.4 million, marking a year-over-year increase of 462.27%. This contributed to the annual value of $484.7 million for FY2024, which is 447.72% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Goodwill & Intangibles stood at $484.7 million for FY2024, which was up 447.72% from $88.5 million recorded in FY2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Goodwill & Intangibles peaked at $484.7 million during FY2024, and registered a low of $2.1 million during FY2022.
  • Over the past 3 years, Recursion Pharmaceuticals' median Goodwill & Intangibles value was $88.5 million (recorded in 2023), while the average stood at $191.8 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Goodwill & Intangibles dropped by 12.21% in 2021 and then soared by 4,100.24% in 2023.
  • Recursion Pharmaceuticals' Goodwill & Intangibles (Yearly) stood at $2.5 million in 2020, then decreased by 12.21% to $2.2 million in 2021, then dropped by 3.61% to $2.1 million in 2022, then surged by 4,100.24% to $88.5 million in 2023, then surged by 447.72% to $484.7 million in 2024.